ACS Latest News Archive
N-terminal pro-B-type natriuretic peptide and growth differentiation factor-15 provide prognostic information in patients with ACS.
Mechanical chest compression devices are not superior to conventional, high-quality manual chest compressions.
The influence of weather on the incidence of myocardial infarction was examined.
Substantial differences were found between black and white participants in demographic, socioeconomic, psychosocial, clinical, disease severity, and health status characteristics.
Coronary artery bypass grafting may be a superior revascularization strategy in patients with diabetes and multivessel disease.
Low hs-cTnI levels may identify patients with CAD who have a low medium-term risk for adverse cardiovascular events.
Combined treatment with pitavastatin and ezetimibe may be beneficial in patients with acute coronary syndrome and without hypertension for secondary prevention.
Investigators examined whether influenza is an independent risk factor for the development of acute myocardial infarction.
A strong association between antiphospholipid positivity and first-time MI may represent a risk factor for myocardial infarction.
The FDA has approved Invokana (canagliflozin) to reduce the risk of major CV events.
A novel point-of-care assay was shown to provide results within 15 minutes, thereby facilitating rapid risk stratification of patients with suspected acute MI.
Coronary computed tomography angiography is a reliable tool to assess long-term cardiovascular risk in suspected CCS.
Single-stage complete coronary revascularization appears to be superior to culprit-only lesion intervention in multivessel disease ACS.
Patients recovering from sepsis had an elevated risk for myocardial infarction or stroke in the first 4 weeks after hospital discharge compared to the general population.
Unrecognized MI detected by cardiac magnetic resonance imaging has similar mortality rates over the long term compared with recognized MI.
There is no difference between heparin and bivalirudin in terms of platelet aggregation or coagulation markers after pretreatment with ticagrelor in patients undergoing PPCI.
Evidence suggests a possible role for inflammation in the association between MS and myocardial infarction risk.
Same day hospital discharge has the potential increase the overall value of PCI care and save US hospitals approximately $577 million if implemented more consistently.
Elevated baseline D-dimer levels were associated with an increased risk for adverse cardiovascular outcomes.
In-hospital treatment of adult community-acquired pneumonia with corticosteroids may be associated with a lower MI risk.
The use of the QRS-T angle with standard ECG criteria improved diagnostic accuracy for NSTEMI.
Angiotensin-converting enzyme inhibitors reduced the incidence of revascularization and major adverse cardiac events, but had no beneficial effect on total deaths or recurrence of myocardial infarction.
The effects of using high-sensitivity cardiac troponin I assays in patients with suspected acute coronary syndrome were assessed.
Ticagrelor without aspirin offered no additional benefits compared with conventional dual antiplatelet therapy in patients undergoing PCI for either CAD or ACS.
Net adverse cardiac events occurred in 15.2% of patients with radial access and 17.2% with femoral access while undergoing invasive therapies for acute coronary syndrome.
Up-titration to a high-intensity statin occurred in only 37.7% of patients with diabetes after an acute myocardial infarction.
The new rapid rule-out for MI protocol had sensitivity and negativity predictive values of 100% and a specificity of 86%.
Investigators examined the outcomes of using various beta-blockers in patients with type 2 diabetes after a myocardial infarction.
Siblings of patients with rheumatoid arthritis appear to have an increased risk for acute coronary syndrome, which suggests there is a shared susceptibility between the 2 conditions.
Dabigatran may be associated with a risk reduction of major vascular complications in patients who develop a myocardial injury after noncardiac surgery.
The 0/1 hour algorithm was superior to the 0/3 hour algorithm for ruling out acute myocardial infarction.
Investigators examine the effects of the PCSK9 inhibitor alirocumab in patients with recent acute coronary syndrome and diabetes.
When patient risk was predicted using ACTION ICU model, the likelihood of a complication developing that required ICU care increased >10-fold from the lowest to the highest scores.
Aldosterone antagonists significantly reduced the risk for mortality in patients with ST-segment elevation myocardial infarction without heart failure.
Investigators examined the time to first event composing of cardiovascular death, myocardial infarction, or stroke.
Investigators conducted a randomized, double-blinded, placebo-trolled trial in patients with T2D after an acute coronary syndrome.
Liraglutide may reduce the incidence of myocardial infarction in patients who have a high cardiovascular risk with type 2 diabetes.
Patients with confirmed or suspected acute myocardial infarction do not benefit from supplemental oxygen therapy.
Major adverse cardiovascular events were not reduced in patients with acute coronary syndrome undergoing planned percutaneous coronary intervention when given 2 loading doses of atorvastatin.
Women are less likely than men to fill a high-intensity statin prescription following hospitalization for myocardial infarction.
Although varenicline was effective for short-term smoking cessation, more than half of the patients in the EVITA trial relapsed after 1 year.
Two analyses were conducted, one during the training phase and the second during the validation phase of the study.
Time from first medical contact to primary percutaneous coronary intervention is inversely linked to short-term survival in STEMI.
In patients with diabetes who had an acute myocardial infarction, the acute-to-chronic glycemic ratio was a better predictor of mortality compared with baseline glycemia levels.
One lot of clopidogrel, a platelet inhibitor, has been recalled due to mislabeling.
Patients with multivessel coronary artery disease and diabetes may benefit more from coronary artery bypass grafting surgery vs percutaneous coronary intervention.
The American College of Cardiology and the American Heart Association have released updated quality and performance measures for STEMI and NSTEMI management.
The researchers concluded abacavir-containg ART does not increase the risk of coronary artery disease or myocardial infarction
The European Society of Cardiology has released new guidelines regarding treatment strategies for acute myocardial infarction and STEMI.
In patients undergoing percutaneous coronary intervention for either STEMI or NSTEMI, bivalirudin and heparin produce similar outcomes.
Supplemental oxygen therapy does not decrease the risk for 1-year all-cause mortality in patients with suspected myocardial infarction.
In high-risk patients with atherosclerotic disease, canakinumab may help reduce the incidence of cardiovascular events.
In patients with non-ST-elevation acute coronary syndromes, an early invasive treatment strategy does not significantly reduce mortality rates.
Patients with atrial fibrillation but without known coronary artery disease may not be at an increased risk for coronary events, despite elevated high-sensitivity troponin T levels.
In patients with acute myocardial infarction without heart failure, beta-blockers did not reduce mortality risk at 1 year.
XyloCor's XC001 is a potential therapy for patients with chronic angina.
Sensitivity of the acute myocardial infarction risk classification ranged from 87.5% to 100%, and the pooled sensitivity estimate was 98.7%.
Compared with New York counties without trans fatty acid restrictions, those with restrictions showed a significantly greater decline in combined myocardial infarction and stroke events.
Cardiac magnetic resonance was superior to transthoracic echocardiogram in identifying a pathologic substrate in patients with out-of-hospital cardiac arrest.
Patients with undiagnosed chest pain in primary care rarely undergo diagnostic testing, but experience an increased risk of both fatal and non-fatal CV events.
Women with ST-segment elevation myocardial infarction often experience prehospital delays to reperfusion.
Atrial fibrillation was associated with a higher risk of adjusted in-hospital mortality and bleeding complications after both PCI and CABG.
Data from almost 15,000 patients were analyzed to determine the links among age, acute coronary syndrome severity, and 30-day mortality.
Pioglitazone reduced the risk of acute coronary syndromes, including type 1 myocardial infarction.
Patients with diabetes presented with ST-segment elevation myocardial infarction symptoms, on average, 50 minutes later than patients without diabetes.
In-hospital mortality was elevated among those who presented with cardiogenic shock during their index hospitalization.
Significantly decreased platelet reactivity occurred in patients who were given a new statin or an increased dose of a previous statin.
Tumor necrosis factor-α inhibiting drugs were shown to reduce the risk of myocardial infarction in rheumatoid arthritis.
Although current guidelines recommend delaying noncardiac surgery for 6 to 12 months after drug-eluting stent implantation, new data suggest surgery may be performed earlier.
Patients in the shared decision making group had greater knowledge about their risk for acute coronary syndrome and options for care.
Patients with acute coronary syndrome had significantly higher odds of committing suicide compared with healthy individuals.
PCKS9 and HMGCR variants were associated with similar protective effects on cardiovascular event risk and diabetes risk.
The cangrelor alone and clopidogrel-GPI groups did not have significantly different rates of the primary efficacy end point.
Using primary percutaneous coronary intervention or a pharmacoinvasive strategy results in similar outcomes for patients with STEMI.
PCI in patients with chronic total occlusion of the left anterior descending coronary artery had significantly improved LVEF compared with control patients.
Cangrelor provided similar perioprocedural benefits, as well as reduced risk of bleeding, as clopidogrel in patients with stable angina and acute coronary syndromes.
Researchers studied patients with acute MI or heart failure to determine if any postdischarge readmissions were potentially preventable.
STEMI patients were more likely to receive PCI, but mortality risk was still increased after multivariable adjustment, compared with NSTEMI patients.
Patients with STEMI who present off-hours do not have worse outcomes than those who present during the workday.
Long-term dual antiplatelet therapy was associated with reduced MACE in patients who underwent complex percutaneous coronary intervention.
After multivariate adjustment for baseline imbalances, researchers found no significant differences for the primary efficacy end point between genders.
Researchers observed a "significant inverse correlation" between P2Y12 reaction units and hemoglobin.
Rate of thrombocytopenia was significantly higher for patients assigned to phosphate-buffered tirofiban, but not those assigned to unfractionated heparin or citrate-buffered tirofiban.
High-sensitivity reporting did not reduce death or new or recurrent acute coronary syndrome compared with standard reporting.
No significant differences in the primary or safety outcomes with either bioresorbable cardiac matrix or saline.
The proportion of patients who presented directly to a PCI-capable center treated within STEMI guideline goals increased from 59% to 61%.
OMEGA-REMODEL study results found an association between omega-3 fatty acids and reduction in adverse effects after acute MI.
The parsimonious risk model is a valid instrument for risk adjustment and risk stratification in acute myocardial infarction.
Myocardial infarction was associated with a high mortality rate even after percutaneous coronary intervention.
Researchers conducted an analysis to investigate major adverse events in acute coronary syndrome patients with diabetes using data from the PROSPECT study.
Intravascular brachytherapy may work as a short-term treatment option in patients with recurrent drug-eluting stent in-stent restenosis.
A full dose of bivalirudin infusion (1.75 mg/kg/h) may mitigate acute stent thrombosis with an increased risk of major bleeding.
Sleep-disordered breathing was a significant predictor for MACCE, along with increase in age, decrease in LVEF and mean SaO2, and the absence of either beta-blocker or statin treatment.
Ischemic memory imaging with myocardial contrast echocardiography in non-infarcted tissue is possible in animal models using the complement-mediated interaction between phosphatidylserine -containing microbubbles.
LEADER trial results demonstrated that liraglutide lowered first occurrence of death from cardiovascular causes in patients with type 2 diabetes.
Heart failure is a particularly powerful predictor of mortality in patients who have both coronary heart disease and type 2 diabetes.
Researchers tested efficacy and safety of high mechanical index impulses from a diagnostic ultrasound transducer during intravenous microbubble infusion.
Previous myocardial infarction was associated with a greater risk for late ischemic events compared to no myocardial infarction history.
The device success rate with COMBO stent was 98.7% and stenosis of more than 20% occurred after the procedure in 0.9% of patients.
Bleeding Academic Research Consortium scale can independently predict 1-year mortality in patients with acute coronary syndromes without ST-segment elevation.
The Cardiology Advisor Articles
- Cardiac Troponin Elevation Predicts Major Adverse Events Even Without Specific Diagnosis
- How Has the Medicaid Expansion Affected Patients Hospitalized With Acute MI?
- Macitentan Not Superior to Placebo for Improving Exercise Capacity in Eisenmenger Syndrome
- Association Between Statins and Depression Likely Mediated by Confounding
- Occupational Metal, Pesticide Exposure May Be Associated With Increased CVD Risk
- ASH Develops Practice Guidelines for Venous Thromboembolism
- Tetralogy of Fallot: Long-Term Outcomes After Surgical Repair
- Cardiac Troponin Elevation Predicts Major Adverse Events Even Without Specific Diagnosis
- Catheter Ablation Superior to Drug Therapy for Atrial Fibrillation in Heart Failure
- Trends in Endocarditis Incidence After Implementation of 2007 AHA Recommendations
- Researchers Identify Golden Ratio Between Pulmonary Pressure Components in PAH
- FDA: Potential Increased Mortality With Paclitaxel-Coated Balloons, Stents for PAD
- Inhaled Dry Powder Formulation of Treprostinil Well Tolerated in PAH
- Elevated Myocardial T1 Associated With Increased Septal Angle in PAH
- Pulmonary Hypertension Intensive Care Options Depend on Treatment Goals